DoW Ovarian Cancer, Clinical Trial Award
This grant funds clinical trials testing new treatments, drugs, devices, or technologies to improve ovarian cancer care and outcomes.
Funder: Dept. of the Army -- USAMRAA
Due Dates: September 15, 2026 (Pre-Application/LOI) | October 1, 2026 (Full Application) | October 6, 2026 (End of Verification)
Funding Amounts: Up to $2.8 million total costs per award (max 4 years); ~2 awards; $5.6M total program funding.
Summary: Supports rapid implementation of clinical trials with high potential to impact ovarian cancer treatment or management.
Key Information: Letter of Intent required before full application; open to all independent investigators; clinical trials only.
Description
This opportunity supports the rapid execution of clinical trials aiming to significantly improve the treatment or management of ovarian cancer. Projects may range from small, early-phase proof-of-concept studies to large-scale efficacy trials, including trials of new drugs, biologics, devices, clinical guidance, or emerging approaches. Only applications proposing true clinical trials (not preclinical or retrospective studies) are eligible. The program places special emphasis on robust study design, inclusion of consumer advocates, and demonstration of access to the necessary patient populations and interventions.
